{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:09:24Z","timestamp":1785186564637,"version":"3.55.0"},"reference-count":26,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Histone deacetylase (HDAC) inhibitors have shown cardioprotective or renoprotective effects in various animal models. Our study proposed that the HDAC inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system (RAS) activity in rats with transverse aortic constriction (TAC)-induced pressure overload cardiac hypertrophy. Cardiac remodelling was evaluated using echocardiography. Cardiac hypertrophy was visualized with haematoxylin and eosin staining, and related gene (Nppa and Nppb) expression was quantified by quantitative real-time polymerase chain reaction (qRT-PCR). Cardiac and renal fibrosis were visualized with picrosirius red and trichrome staining, respectively. Fibrosis related gene (Collagen-1, Collagen-3, Ctgf, and Fibronectin) expression was determined by qRT-PCR. Serum concentrations of RAS components (renin, angiotensin II, and aldosterone) were quantified by enzyme-linked immunosorbent assay and related gene (Renin and Agtr1) expression was determined by qRT-PCR. TAC-induced pressure overload cardiac hypertrophy, which mimics hypertensive heart disease, increased cardiac remodelling, cardiac hypertrophy, and fibrosis in our rat models. Upon treatment with mocetinostat, there was a significant regression in cardiac remodelling, cardiac hypertrophy, and fibrosis in TAC rats. Additionally, pressure overload-induced renal fibrosis and activity of RAS-related components were increased in TAC rats, and were decreased on treatment with mocetinostat. The present study indicates that mocetinostat, an HDAC inhibitor, has cardiorenal protective effects in rats with TAC-induced pressure overload cardiac hypertrophy and offers a promising therapeutic agent for hypertension-related diseases.<\/jats:p>","DOI":"10.31083\/j.rcm2203113","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T02:35:45Z","timestamp":1632623745000},"source":"Crossref","is-referenced-by-count":15,"title":["Histone deacetylase inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system activity in rats with transverse aortic constriction-induced pressure overload cardiac hypertrophy"],"prefix":"10.31083","volume":"22","author":[{"given":"Gun Jik","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, 41944 Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, 41944 Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjo","family":"Lee","sequence":"first","affiliation":[{"name":"Emerging Infectious Disease Vaccines Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, 28159 Cheongju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Woon","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Pusan National University Hospital, Pusan National University School of Medicine, 49241 Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Progress in Cardiovascular Diseases. 2020; 63: 10\u201321.","DOI":"10.1016\/j.pcad.2019.11.009"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Jung H, Lee E, Kim I, Song JH, Kim GJ. Histone deacetylase inhibition has cardiac and vascular protective effects in rats with pressure overload cardiac hypertrophy. Physiological Research. 2019; 68: 727\u2013737.","DOI":"10.33549\/physiolres.934110"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Taddei S, Nami R, Bruno RM, Quatrini I, Nuti R. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Failure Reviews. 2011; 16: 615\u2013620.","DOI":"10.1007\/s10741-010-9197-z"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Leoncini G, Viazzi F, Parodi D, Vettoretti S, Ratto E, Ravera M, et al. Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension. Hypertension. 2003; 42: 14\u201318.","DOI":"10.1161\/01.HYP.0000075789.58883.73"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Amann K, Rychlik I, Miltenberger-Milteny G, Ritz E. Left ventricular hypertrophy in renal failure. Kidney International Supplements. 1998; 68: S78\u2013S85.","DOI":"10.1046\/j.1523-1755.1998.06818.x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, et al. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. Journal of Molecular and Cellular Cardiology. 2014; 67: 112\u2013125.","DOI":"10.1016\/j.yjmcc.2013.12.013"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Yoon GE, Jung JK, Lee YH, Jang BC, In Kim J. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. 2020; 393: 491\u2013500.","DOI":"10.1007\/s00210-019-01749-5"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clinical Science. 2013; 124: 651\u2013662.","DOI":"10.1042\/CS20120504"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Jung H, Lee E, Kim I, Kim GJ. Histone Deacetylase Inhibition Attenuates Aortic Remodeling in Rats under Pressure Overload. BioMed Research International. 2020; 2020: 4705615.","DOI":"10.1155\/2020\/4705615"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kee HJ, Bae EH, Park S, Lee KE, Suh SH, Kim SW, et al. HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6\/HDAC8 enzyme activity. Kidney and Blood Pressure Research. 2013; 37: 229\u2013239.","DOI":"10.1159\/000350148"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA, et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. British Journal of Pharmacology. 2010; 159: 1408\u20131417.","DOI":"10.1111\/j.1476-5381.2010.00637.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lee E, Song MJ, Lee HA, Kang SH, Kim M, Yang EK, et al. Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats. The Korean Journal of Physiology & Pharmacology. 2016; 20: 477\u2013485.","DOI":"10.4196\/kjpp.2016.20.5.477"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006; 113: 51\u201359.","DOI":"10.1161\/CIRCULATIONAHA.105.559724"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Wu WP, Tsai YG, Lin TY, Wu MJ, Lin CY. The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3(+)IL-17(+) T cells. BMC Nephrology. 2017; 18: 225.","DOI":"10.1186\/s12882-017-0630-6"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Choi HS, Song JH, Kim IJ, Joo SY, Eom GH, Kim I, et al. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Scientific Reports. 2018; 8: 11546.","DOI":"10.1038\/s41598-018-30008-5"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opinion on Investigational Drugs. 2011; 20: 823\u2013829.","DOI":"10.1517\/13543784.2011.577737"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Lyu X, Hu M, Peng J, Zhang X, Sanders YY. HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis. Therapeutic Advances in Chronic Disease. 2019; 10: 1\u20139.","DOI":"10.1177\/2040622319862697"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America. 1991; 88: 8277\u20138281.","DOI":"10.1073\/pnas.88.18.8277"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circulation Research. 2012; 110: 739\u2013748.","DOI":"10.1161\/CIRCRESAHA.111.258426"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Nural-Guvener HF, Zakharova L, Nimlos J, Popovic S, Mastroeni D, Gaballa MA. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis & Tissue Repair. 2014; 7: 10.","DOI":"10.1186\/1755-1536-7-10"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Munoz-Durango N, Fuentes CA, Castillo AE, Gonzalez-Gomez LM, Vecchiola A, Fardella CE, et al. Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension. International Journal of Molecular Sciences. 2016; 17: 797.","DOI":"10.3390\/ijms17070797"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. Journal of Human Hypertension. 2014; 28: 74\u201379.","DOI":"10.1038\/jhh.2013.55"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sun HJ. Current Opinion for Hypertension in Renal Fibrosis. Advances in Experimental Medicine and Biology. 2019; 1165: 37\u201347.","DOI":"10.1007\/978-981-13-8871-2_3"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Khan S, Jena G, Tikoo K. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat. Experimental and Molecular Pathology. 2015; 98: 230\u2013239.","DOI":"10.1016\/j.yexmp.2015.01.003"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ryu Y, Kee HJ, Sun S, Seok YM, Choi SY, Kim GR, et al. Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension. PLoS ONE. 2019; 14: e0213186.","DOI":"10.1371\/journal.pone.0213186"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Kee HJ, Ryu Y, Seok YM, Choi SY, Sun S, Kim GR, et al. Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice. Clinical Hypertension. 2019; 25: 13.","DOI":"10.1186\/s40885-019-0118-8"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/3\/10.31083\/j.rcm2203113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:40:54Z","timestamp":1732729254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/3\/10.31083\/j.rcm2203113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["1632453109144-369830911"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2203113","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"article-number":"1037"}}